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ABSTRACT 
Background: Polypharmacy is an important challenge in clinical practice. We aimed at 
determining the effect of polypharmacy on functional outcome and treatment effect of 
alteplase in acute ischemic stroke. 
Methods: Post-hoc analysis of the randomized, placebo-controlled WAKE-UP trial of MRI-
guided intravenous alteplase in unknown onset stroke. Polypharmacy was defined as intake 
of ≥5 medications at baseline. Comorbidities were assessed by the Charlson Comorbidity 
Index (CCI). The primary efficacy variable was favorable outcome defined by a score of 0-1 
on the modified Rankin Scale at 90 days. We used logistic regression analysis to test for an 
association of polypharmacy with functional outcome, and for interaction of polypharmacy 
and the effect of thrombolysis. 
Results: Polypharmacy was present in 133/503 (26%) patients. Patients with polypharmacy 
were older (mean age 70 vs 64 years; P<0.0001) and had a higher score on the National 
Institutes of Health Stroke Scale at baseline (median 7 vs 5; P=0.0007). A comorbidity load 
defined by a CCI score ≥2 was more frequent in patients with polypharmacy (48% vs 8%; 
P<0.001). Polypharmacy was associated with lower odds of favorable outcome (adjusted 
odds ratio 0.50, 95% CI, 0.30-0.85; P=0.0099), while the CCI score was not. Treatment with 
alteplase was associated with higher odds of favorable outcome in both groups, with no 
heterogeneity of treatment effect (test for interaction of treatment and polypharmacy, 
P=0.29). 
Conclusion: In stroke patients, polypharmacy is associated with worse functional outcome 
after intravenous thrombolysis independent of comorbidities. However, polypharmacy does 
not interact with the beneficial effect of alteplase. 
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INTRODUCTION 
Polypharmacy, commonly defined as an intake of five or more drugs (1), is considered an 
important and growing challenge in clinical practice. While there is no strong evidence to 
support the use of any particular threshold, the risk of drug-related problems seems to 
increase with each additional medication prescribed. The most important factors driving 
polypharmacy are age and multimorbidity (2, 3). Polypharmacy has been associated with a 
significant burden in frequency of hospitalization, length of hospital stay, in-hospital deaths, 
disability and adverse drug reactions (3). In addition, previous studies revealed that 
polypharmacy is associated with higher rates of complications and mortality in elderly 
patients (4-7). 
Stroke remains one of the leading causes of death and disability worldwide (8), and the risk 
of stroke is increased in the elderly and in patients with multiple comorbidities. It is well 
known that ischemic stroke is associated with cardiovascular risk factors, such as arterial 
hypertension, diabetes, hypercholesterolemia and atrial fibrillation (AF), which, if treated 
according to current guidelines, commonly lead to polypharmacy (9-11). However, data on 
the association between polypharmacy and stroke outcome as well as acute stroke treatment 
is limited.  
In the present study, our first objective was to study whether polypharmacy is associated with 
functional outcome in patients with acute ischemic stroke. Second, we aimed to study a 
possible effect of polypharmacy on the benefit of treatment with intravenous alteplase. We 
investigated these objectives in a post-hoc analysis of the WAKE-UP study. 
 
METHODS AND MATERIALS  
Study design 
In this exploratory secondary post-hoc analysis, we reviewed medical history of all patients 
randomized in WAKE-UP to evaluate polypharmacy and pre-existing comorbidities. WAKE-
UP was a multicenter, randomized, double-blind, placebo-controlled clinical trial to study the 
efficacy and safety of intravenous thrombolysis with alteplase in patients with an acute stroke 
of unknown onset time, guided by MRI. Inclusion criteria comprised the mismatch between 
an acute ischemic lesion visible on diffusion-weighted imaging (DWI) but with no 
corresponding marked parenchymal hyperintensity on fluid-attenuated inversion recovery 
(FLAIR) as a surrogate marker of lesion age, indicating that the stroke onset most likely lies 
within 4.5 hours (12). A
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In this analysis, we examined demographic characteristics, medical history, clinical and 
imaging data at baseline and follow-up, including final follow-up at 90 days after stroke. 
Polypharmacy was defined as the intake of ≥5 medications at baseline according to the most 
common definition (1). Pre-existing comorbid conditions were assessed and summarized in 
the Charlson Comorbidity Index (CCI) (13). The CCI is an extensively validated index and 
includes 19 diseases, which are weighted according to their association with mortality. We 
used a modified version of the CCI score which was adjusted and has shown its validity for 
use in stroke outcome studies (14, 15). In this adjusted version, diagnosis and symptoms of 
the acute ischemic stroke are disregarded, and age also does not count for the score.  
 
Outcome measures and endpoints 
Clinical outcome was assessed at 90 days after stroke. Evaluation of efficacy outcomes 
followed the clinical endpoints as defined in the WAKE-UP trial. The primary endpoint was 
favorable outcome defined as a score of 0-1 on the modified Rankin Scale (mRS). Secondary 
endpoint in this analysis comprised the ordinal analysis of the mRS (“shift analysis”). Safety 
outcomes were mortality, and the incidence of symptomatic intracranial hemorrhage (SICH) 
according to the protocol of SITS-MOST on follow-up imaging 22-36 hours after treatment.  
 
 
Statistical analysis 
Baseline characteristics were compared between patients with and without polypharmacy. 
Statistical analyses of treatment effects were performed in the intention-to-treat population 
for all patients with available information for clinical endpoints. Primary and secondary 
efficacy outcome were assessed using an unconditional logistic regression analysis including 
polypharmacy and the CCI score as a continuous parameter, fitted to estimate the OR and its 
95% CI interval. The categorical shift in the distribution of mRS scores was analyzed by 
fitting a proportional-odds logistic regression model.  
The CCI score comprises a wide range of comorbidities but does not include important 
cardiovascular diseases such as arterial hypertension, AF, and hypercholesterolemia, which 
are frequent in stroke patients and may also be associated with stroke outcome. To account 
for this, and to test for the association of individual comorbidities with favorable outcome, 
we calculated another model including polypharmacy, NIHSS at baseline, age, treatment, and 
the individual comorbidities summarized in the CCI amended by arterial hypertension, AF, 
and hypercholesterolemia. We excluded comorbidities which were present in <10 patients. 
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To identify significant predictors of favorable outcome among this large list of variables, we 
fitted a backwards multivariable logistic regression model. 
To investigate the interaction between polypharmacy and treatment effect on the primary 
endpoint, we used an unconditional logistic regression model, relating the log-odds of the 
primary outcome with the covariate of interest, the treatment group, and their interaction. The 
interaction term was tested with the Wald-Chi-squared test, and the treatment effect (odds 
ratio [OR]) and its 95% confidence interval (CI) was estimated for each category of the 
categorical variable. All analyses were adjusted for the stratification parameters age and 
National Institutes of Health Stroke Scale (NIHSS). All tests were carried out with a two-
sided alpha level of 5% without correction for multiple comparisons. 
 
Standard protocol approvals, registrations, and patient consents 
Patients or their legal representatives provided written informed consent according to national 
and local regulations. There was an exception from explicit informed consent in emergency 
circumstances in some countries. For each study site, the competent authorities and the 
corresponding ethics committee approved the trial. The detailed trial protocol has been 
published together with its main results (12). The trial was registered at ClinicalTrials.gov 
number (NCT01525290) and EudraCT (2011-005906-32). 
 
Data Availability Statement 
The full trial protocol and the statistical analysis plan of WAKE-UP have already been 
published along with the main trial publication (12).  Individual patients data, after de-
identification, will be shared with the Virtual International Stroke Trials Archive (VISTA) 
and be accessible for researchers who provide a methodologically sound proposal according 
to the VISTA rules (http://www.virtualtrialsarchives.org/vista/). 
 
RESULTS 
Patient characteristics 
Of 503 patients randomized in WAKE-UP, polypharmacy was present in 133 patients (26%, 
Figure 1). We observed a continuous increase of patients taking typical drugs for 
cardiovascular prevention (i.e., antiplatelets, statins, antihypertensives and antidiabetics) with 
increasing number of drugs (Figure 2). In the polypharmacy group, >50% of patients were on 
a combination of antiplatelets, statins, and antihypertensives.  A
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Clinical characteristics in patients with and without polypharmacy are shown in Table 1. 
Patients with polypharmacy were older, with a mean age (SD) of 70 (8) years compared with 
64 (12) years in patients without polypharmacy (P<0.0001). Those with polypharmacy were 
more severely affected, with a higher median NIHSS score on admission of 7 points 
compared to 5 points in those without polypharmacy (P=0.0007). Overall, patients with 
polypharmacy had more comorbidities, with 64 patients (48%) with a CCI score ≥2 in the 
polypharmacy group, compared to 30 patients (8%) in the no polypharmacy group (P<0.001). 
Regarding cardiovascular risk factors, arterial hypertension (115 [86%] vs 151 [41%] 
patients; P<0.0001), diabetes mellitus (55 [41%] vs 27 [7%] patients; P<0.0001),  
hypercholesterolemia (82 [62%] vs 96 [26%] patients; P<0.0001) and AF (29 [22%] vs 30 
[8%] patients; P=0.0002) were more prevalent in patients with polypharmacy. DWI lesion 
volume at baseline, frequency of vessel occlusion, as well as time from recognition of 
symptoms to treatment initiation did not differ between the groups. 
 
Influence of polypharmacy on stroke outcome  
Information on the primary endpoint was available for 490 patients (130 with polypharmacy 
and 360 without polypharmacy). Among all randomized patients, polypharmacy was 
independently associated with lower odds of favorable outcome, while pre-existing 
comorbidities, indicated by the sum score of the CCI, were not (Table 2). Favorable outcome 
was observed in 43 of 130 patients (33%) in the polypharmacy group and in 190 of 360 
patients (53%) in the no polypharmacy group (absolute difference, 19.7%; adjusted OR, 0.50 
[95% CI, 0.30-0.85]; P=0.0099).  
In the ordinal analysis of the mRS at 90 days, polypharmacy was associated with a shift 
towards worse functional outcome (adjusted common odds ratio 0.68, 95% CI, 0.45-1.03; 
P=0.070; Figure 3). The CCI score again was not significantly associated with functional 
outcome (P=0.47). 
In backwards multivariable logistics regression analysis including polypharmacy, CCI 
subitems and additional cardiovascular comorbidities, the most parsimonious model showed 
that polypharmacy (adjusted OR, 0.56 [95% CI, 0.35-0.88]; P=0.0013) and NIHSS score 
(adjusted OR, 0.12 [95% CI, 0.06-0.21]; P<0.0001) were associated with lower odds of 
favorable outcome, while treatment with alteplase showed a positive association with 
favorable outcome (adjusted OR, 1.60 [95% CI, 1.08-2.36]; P=0.023). Subitems of the CCI, 
arterial hypertension, AF, and hypercholesterolemia were not associated with functional 
outcome.  
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Interaction of polypharmacy and treatment effect 
Among all randomized patients, treatment with alteplase was associated with higher odds of 
favorable outcome with no heterogeneity of treatment effect for subgroups defined by 
polypharmacy (test for interaction, P=0.29; Figure 4). The adjusted OR for favorable 
outcome with alteplase was 2.33 (95% CI, 1.04-5.20) in patients with polypharmacy, and 
1.43 (95% CI, 0.91-2.22) in patients without polypharmacy.  
 
Mortality and Safety outcomes in patients with polypharmacy 
At 90 days, 6 patients in the polypharmacy group had died (4.5%), while 7 patients (1.9%) 
had died in the no polypharmacy group. There were 2 (1.5%) cases of SICH meeting criteria 
of SITS-MOST in the polypharmacy group and 4 (1.1%) cases in the no polypharmacy 
group. 
 
DISCUSSION 
In this secondary post-hoc analysis of the WAKE-UP trial, we studied the effect of 
polypharmacy on outcome and efficacy of reperfusion treatment in acute ischemic stroke, 
motivated by the growing prevalence of polypharmacy and missing recommendations for 
action in clinical practice. Our study yielded two major findings. First, we observed that 
polypharmacy, independently of pre-existing comorbidities, was associated with worse 
functional outcome after ischemic stroke. Second, there was no heterogeneity of treatment 
effect with regard to the presence of polypharmacy. Thus, our data suggest that treatment 
with alteplase is of similar benefit in patients with polypharmacy as in those without 
polypharmacy.  
Polypharmacy is a growing challenge in clinical practice, with 10% of the population and 
30% of older adults in the United States taking five or more drugs simultaneously (16). 
Similarly high prevalence is reported in other countries (e.g., the United Kingdom (17), 
Germany (18), and China (19)). Due to aging of the population, the importance of 
polypharmacy on a societal level is likely to increase over the next years. With 26%, the 
prevalence of polypharmacy among the patients randomized in WAKE-UP was high, 
although trial design criteria led to exclusion of very elderly patients (>80 years of age) and 
those with pre-stroke disability (mRS >1). Given that both polypharmacy and stroke are 
associated with higher age and comorbidities, we assume that polypharmacy is even more 
common in the general stroke population.  
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Previous studies have identified polypharmacy as an indicator of mortality in elderly patients 
(5, 6). In our study, patients with polypharmacy were older and had more comorbidities, 
including cardiovascular risk factors and diseases, but our analysis did not show an influence 
of polypharmacy on mortality. This may be explained by the fact that the cohort size was 
small, patients’ age was relatively low, and premorbid disability was excluded, as compared 
to unselected stroke populations, and finally overall mortality in our trial was low (<3%). 
Additionally, it has to be considered that in recent studies, mortality was assessed over a 
longer period of time and not restricted to three months follow-up of a certain event. 
In the context of polypharmacy and stroke, there are few studies investigating the influence 
of polypharmacy on stroke occurrence. In patients with AF, which in turn represent a 
population at risk for stroke, polypharmacy was associated with a higher risk for 
cardiovascular death independently of age and comorbidities. However, a significant 
association between polypharmacy and stroke was not observed (20). A retrospective study 
showed that an increased number of drugs during hospitalization was negatively associated 
with both functional recovery and possibility of home discharge among geriatric stroke 
patients (21). Based on these findings, it is reasonable to assume that polypharmacy adversely 
affects stroke outcome. Our study enabled the first systematic investigation of the effect of 
polypharmacy on outcome and intravenous thrombolysis among patients with ischemic 
stroke in a randomized clinical trial. Indeed, our analysis revealed that polypharmacy, 
independently of pre-existing comorbidities, was associated with worse functional outcome 
after ischemic stroke compared to no polypharmacy, with an absolute 20% less patients 
achieving a favorable outcome at three months after stroke.  
Of note, this effect was not driven by the higher burden of comorbidities in patients with 
polypharmacy, as might have been conceivable. Moreover, in multivariable analysis neither 
individual CCI items nor other important cardiovascular comorbidities such as arterial 
hypertension, AF and hypercholesterolemia, showed a significant association with functional 
outcome, while polypharmacy did consistently across all models. It has to be considered that 
this finding may be attributable to a selection effect in our study based on data from a 
randomized controlled clinical trial with strict inclusion and exclusion criteria. These 
comprise among others the exclusion of patients with malignant diseases and other severe 
comorbidities, as well as an upper age limit. As a result, the proportion of patients with 
severe comorbidities indicated by a CCI score ≥2 in our population was rather small (19%). 
Previous studies of unselected cohorts of stroke patients reported higher rates of severe 
comorbidities ranging from 32% to 43% (14, 15). We cannot rule out that in other stroke 
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cohorts comorbidities may show a greater influence on outcome. Nevertheless, our findings 
suggest that specific effects of polypharmacy might drive worse outcome in stroke patients 
taking ≥5 medications. A possible mechanism that might add to the deleterious effect of 
polypharmacy are drug-drug interactions which were reported to be frequent in acute stroke 
patients (22). Especially serious drug-drug interactions are likely to occur more frequent with 
polypharmacy. 
Although the WAKE-UP trial was not powered to show a significant treatment outcome in 
subgroups of patients, we found that alteplase was associated with favorable outcome in both 
the polypharmacy as well as the no polypharmacy group. There was no significant 
heterogeneity of treatment effect between the subgroups. This finding may come surprising, 
as it could have been assumed that drug-drug interactions also adversely influence the effect 
of intravenous thrombolysis. Obviously, this is not the case, and the result is reassuring, as it 
demonstrates that intravenous thrombolysis is both effective and safe even in patients on 
multiple drugs. Thus, polypharmacy should not affect the decision for thrombolysis.  
There are limitations to our study. Due to the retrospective observational design of the 
analysis of polypharmacy effects, we cannot establish a causal relationship of polypharmacy 
and functional outcome. In addition, as study inclusion and exclusion criteria entailed a 
selected and relatively young sample of stroke patients, generalizability of our results is 
limited. Finally, our analysis was not powered to study specific effects of individual drugs or 
medication classes in detail. 
The results of our study provide novel information on the impact of polypharmacy on stroke 
outcome. There is still only scarce data on polypharmacy in stroke, and further research is 
needed. Polypharmacy is a complex phenomenon, which, besides potential negative effects 
such as the increased risk of side effects and drug-drug-interactions, may also reflect a high 
quality of medical care and adherence to guideline recommendations. 
 
CONCLUSIONS  
Polypharmacy is highly prevalent in stroke patients and associated with worse functional 
outcome after acute ischemic stroke. Polypharmacy does not influence the beneficial effect of 
alteplase, and therefore polypharmacy should not affect the decision for intravenous 
thrombolysis. Further research is required to determine whether strategies for reducing 
polypharmacy may improve outcome of stroke patients.  
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TABLE LEGENDS 
 
Table 1. Baseline characteristics of patients with and without polypharmacy 
 
Table 2. Association of polypharmacy with favorable functional outcome  
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FIGURE LEGENDS 
Figure 1. Number of medications at baseline 
 
Figure 2. Distribution of most frequent cardiovascular drugs over the number of 
medications 
Distribution of the most frequent cardiovascular drugs shows a continuous increase of 
patients taking typical drugs for cardiovascular prevention with increasing number of 
medications.  
 
Figure 3. Distribution of Modified Rankin Scale scores at 90 days after stroke  
Distribution of scores on the modified Rankin Scale reveals a shift towards worse outcomes 
in the polypharmacy group. Modified Rankin Scale scores range from 0 to 6 (0, no 
symptoms; 1, no clinically significant disability; 2, slight disability; 3, moderate disability; 4, 
moderately severe disability; 5, severe disability; and 6, death). 
 
Figure 4. Association of alteplase with favorable outcome 
Forest plots demonstrate a treatment benefit favoring alteplase, with no significant interaction 
between subgroup and treatment outcome.  
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Table 1. Baseline characteristics of patients with and without polypharmacy 
 Patients, No. (%)  
Variable Polypharmacy 
(n=133) 
No polypharmacy 
(n=370) 
P Value 
Age, mean (SD), y 70 (8) 64 (12) <0.0001  
Female 57 (43) 121 (33) 0.04 
Medical history or risk factors       
   Charlson Comorbidity Index score ≥2 64 (48) 30 (8) <0.0001 
   Arterial hypertension 115 (86) 151 (41) <0.0001 
   Diabetes mellitus 55 (41) 27 (7) <0.0001 
   Hypercholesterolemia 82 (62) 96 (26) <0.0001 
   Atrial fibrillation 29 (22) 30 (8) 0.0002 
   History of ischemic stroke 35 (26) 33 (9) <0.0001 
Medication classes    
   Antiplatelets 94 (71) 69 (19) <0.0001 
   Statins 86 (65) 67 (18) <0.0001 
   Antihypertensives 119 (89) 127 (34) <0.0001 
   Antidiabetics 47 (35) 24 (6) <0.0001 
National Institute of Health Stroke 
Scale score, median (IQR) 
7 (4-12) 5 (3-8) 0.0007 
Diffusion-weighted imaging lesion 
volume at baseline, median (IQR), mL 
2.6 (0.9-9) 2.2 (0.7-8.2) 0.51 
Vessel occlusion on time-of-flight 
magnetic resonance angiography 
      
   Large vessel occlusion 28 (21) 70 (19) 0.61 
   Any vessel occlusion 52 (40) 135 (37) 0.6 
Time from symptom recognition to 
treatment initiation, median (IQR), min 
200 (159-237) 185 (148-230) 0.13 
Treatment with Alteplase 63 (47) 191 (52) 0.42 
Abbreviations: IQR, interquartile range.  A
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Table 2. Association of polypharmacy with favorable functional outcome  
Assessment Variable at 90 days Adjusted Odds ratio†
 
(95% CI) P Value 
Primary end point (Modified Rankin Scale 
Score 0-1) 
  
   Polypharmacy  0.50 (0.30-0.85) 0.0099 
   Charlson Comorbidity Index Score 1.04 (0.85-1.26) 0.74 
   Treatment with alteplase 1.60 (1.09-2.36) 0.018 
Secondary end point (“Shift analysis”)   
   Polypharmacy  0.68 (0.45-1.03) 0.070 
   Charlson Comorbidity Index Score 0.94 (0.81-1.10) 0.47 
   Treatment with alteplase 1.60 (1.16-2.21) 0.004 
†The odds ratio was adjusted for the stratification factors age and symptom severity assed by 
the National Institutes of Health Stroke Scale (NIHSS).  
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